Poolbeg Pharma’s Jeremy Skillington talks to Proactive London after signing a deal with CytoReason, a leading artificial intelligence (AI) to provide AI analysis of Poolbeg’s influenza disease progression data derived from human challenge study samples.
Watch the video here.
The post [CytoReason on Proactive] Poolbeg Pharma plan to ‘unlock’ the influenza disease with CytoReason after signing AI deal appeared first on OurCrowd Blog.
